Pharma dominates in climate scorecard; FDA hears need for opioid REMS;

> AstraZeneca and Johnson & Johnson led the pharmaceutical industry in besting 13 other industries on the nonprofit Climate Counts' climate change scorecard, which measures corporate efforts to reduce emissions. Report l Release

> Steve Hayes, director of Novus Medical Detox Center, and Larry Golbom, host of The Prescription Addiction Radio Show testified before the FDA in late May about the need for Risk Evaluation Mitigation Strategies (REMS) for opioids, especially OxyContin. Release

> GlaxoSmithKline has opened a $600 million ($414 million US) vaccine manufacturing plant as part of a 10-year strategy. Article

> Contract manufacturer CoreRx will purchase an 80,000-square-foot facility in Florida for the formulation, analysis and production of clinical trial quantities of pharmaceuticals. Article

> Formulation development and clinical trial materials maker Metrics has consolidated its quality-related operations and promoted Tom Wilson to VP for quality operations. Announcement


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.